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SUMMARY
A 10-month longitudinal household study of pre-school children and their families was
undertaken with monthly visits collecting epidemiological data and nasopharyngeal swabs in
Hertfordshire, England from 2001 to 2002. Pneumococcal culture was with standard methods. In
total, 121 families (489 individuals) took part. Mean prevalence of carriage ranged from 52% for
age groups 0–2 years, 45% for 3–4 years, 21% for 5–17 years and 8% foro18 years. Carriage
occurred more than once in 86% of children aged 0–2 years compared to 36% of those aged
o18 years. The most prevalent serotypes in the 0–2 years age group were 6B followed by 19F,
23F, 6A and 14. Young children were responsible for the majority of introductions of new
serotypes into a household. Erythromycin resistance (alone or in combination) occurred in 10%
of samples and penicillin non-susceptibility in 3.7%. Overall the recently licensed 7-valent
conjugate vaccine (PCV) would protect against 64% of serotypes with no intra-serogroup cross
protection and 82% with such protection. Nasopharyngeal carriage of S. pneumoniae is common
in a UK setting in the pre-conjugate vaccine era. PCV would protect against a large proportion of
carriage isolates. However, the impact of vaccination on non-vaccine serotypes will need to be
monitored.
INTRODUCTION
Streptococcus pneumoniae (Pneumococcus or Pnc) is a
common component of the nasopharyngeal (NP) ﬂora
in healthy individuals, with more than 90 diﬀerent
serotypes identiﬁed. Infection with Pnc ranges from
asymptomatic carriage through a variety of clinically
mild, common mucosal infections (otitis media and
sinusitis) to more serious, less common invasive pres-
entations such as pneumonia, septicaemia and
meningitis [1, 2]. Pnc carriage rates are generally far in
excess of disease rates–with marked variation by age,
serotype and geographical area [3–10].
A heptavalent Pnc conjugate (PCV) vaccine was
licensed in the United States in 2000 for universal use
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in children aged 2–23months and for children aged 24–
59 months who are at increased risk for pneumococcal
disease [11]. This vaccine has now been licensed in
Europe including the United Kingdom, where it has
been recommended since 2001 for children aged from
2 months to 5 years considered at high risk. Dis-
cussions are ongoing whether to include universal
PCV vaccination within the childhood immunization
schedules of many European countries.
In clinical trials, PCV has proved to be protective
for invasive pneumococcal disease caused by vaccine
serotypes [12] as well as reducing their carriage [3],
and hence a possible herd immunity eﬀect. The
observed reduction in vaccine serotypes has also been
associated with an increase in carriage of non-vaccine
serotypes in vaccinated children in carriage studies
[13] and in vaccine trials for PCV against otitis media
[14]. This phenomenon of serotype replacement has
also been explored by mathematical modelling
[15–17]. These observations and models raised the
question of whether such increases in non-
vaccine serotypes may also occur for invasive
disease after large-scale use of the vaccine in the
population: an observation recently made in the
United States [17].
To be able to predict the impact of mass intro-
duction of PCV in the United Kingdom, baseline
information on the epidemiology of Pnc (including
carriage by multiple serotypes) in this setting is
required. Few studies have been published in recent
years on the descriptive epidemiology of pneumo-
coccal carriage in the United Kingdom [8, 18],
and none on the dynamics of infection in a
household setting to enable these evaluations to be
undertaken.
In this study, the prevalence of NP carriage in
households with young children and their families was
studied monthly over a 10-month period in one geo-
graphical area in Southern England. The description
of the households and families, the epidemiology of
pneumococcal carriage including serotype, antibiotic
resistance patterns and coverage of the diﬀerent for-
mulations of the conjugate vaccine (7-, 9-, 11-valent)
are presented in this paper. Detailed analysis of
Pnc transmission within the household and from
the community, with estimates of acquisition and
clearance rates, are reported in Melegaro et al. [19].
In depth analysis of risk factors for Pnc carriage,
serological aspects of carriage and the trans-
mission dynamics of infection will be presented
separately.
MATERIAL AND METHODS
Participants
The index children were aged from birth to 3 years
old at study entry and were recruited by study nurses
together with their entire households. The sampling
framewas the primary health-care child registers of the
fourmain general practices inHertfordshire. The study
started on 1 October 2001, followed by monthly home
visits and was completed by the end of July 2002.
Individuals (and the entire family if the index child
fulﬁlled an exclusion criteria) with the following
conditions were excluded from the study: moderate
to severe disability ; cerebral palsy ; syndromes and
neurological disorders aﬀecting swallowing; ear, nose
and throat (ENT) disorders aﬀecting the anatomy of
the ear (i.e. malformed ears) ; conﬁrmed or suspected
immunodeﬁciency (congenital or acquired); immuno-
suppressive therapy or enrolment in a pneumococcal
vaccine trial.
The local and national ethics committees approved
the study protocol. Written informed consent was
obtained from all adult study participants and from
a parent/guardian of all study children prior to
enrolment.
Study design
The study was a 10-month longitudinal prospective
follow-up of a population-based sample of pre-school
children and their households. A study nurse under-
took monthly visits. At each visit, basic epidemio-
logical data on each household member and the
household were gathered together with NP swabs and
other biological specimens including serum and urine.
Following recruitment of a family, a study nurse
administered a pre-tested structured, detailed ques-
tionnaire at the initial visit to each family member.
Both household and individual data were gathered on
potential risk factors or confounders. Individual data
included age, gender, education, day-care attendance,
smoking, health status, contact history in and out the
house, any medication including antibiotics. House-
hold data included socio-demographic factors such
as type of house, number of rooms and parental
occupation. A shorter questionnaire was administered
at each monthly visit to each family member to gather
information on any changes in individual and house-
hold details.
NP swabs were obtained at the initial home visit
from all family members, followed by monthly swabs
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over the 10-month period. Sampling of absent mem-
bers or members with illness was performed at a later
date but within a 14-day period. Swabs were taken by
the study nurse and transported to the Respiratory
and Systemic Infection Laboratory (RSIL) at the
Central Public Health Laboratory (CPHL), London
within 24 h of collection.
Data were collected on a standard case report form
(CRF), which were doubly entered onto a database
housed at the Communicable Disease Surveillance
Centre (CDSC). Laboratory data were entered on
a laboratory form at CPHL and entered into the
common database.
Determination of sample size
Simulation was used to determine that a total of 150
index children with a stable prevalence of carriage and
a mean duration of carriage of 1 month would be
suﬃcient to estimate a 25% acquisition rate per
month within the index children with a 95% conﬁ-
dence interval (CI) of 22–29%.
Sample collection
The study nurse used a ﬂexible wire shaft with a cal-
cium alginate tip to obtain NP swabs. All NP samples
were handled according to the Standard Operating
Procedures of the WHO–Pnc trialists’ network [20].
Brieﬂy, the swab was plated immediately by the study
nurse, ﬁrst on non-selective Columbia horse blood
agar then on a Streptococcus selective Columbia
horse blood agar (Oxoid, Basingstoke, UK) for de-
tection of Pnc. The tip was then placed in a medium
containing skim milk, tryptone, glucose, and glycerol
(STGG) [21] and the inoculated plates and STGG
broths were kept cool until transfer to the laboratory.
Laboratory procedures
On arrival at RSIL, the primary pool of inoculum on
both plates was ‘streaked-out’ with a loop and an
optochin disc applied to the primary streak of the
non-selective plate. The STGG broth was subcultured
onto Columbia horse blood agar and Streptococcus
selective Columbia horse blood agar plates. All plates
were incubated overnight with 5% CO2 (18–24 h) and
examined for a-haemolytic colonies with morphology
typical for Pnc. To identify Pnc, suitable colonies
from all plates were tested for optochin sensitivity.
The bile solubility test was used if the colony
morphology was suggestive of Pnc but the organism
was optochin resistant. Minimal inhibitory con-
centrations (MICs) of penicillin, erythromycin and
cefotaxime were determined for all conﬁrmed Pnc
isolates by agar dilution as previously described [22].
Isolates were classiﬁed as susceptible, intermediate or
resistant to the agents tested using the criteria of the
British Society for Antimicrobial Chemotherapy [23].
Pneumococcal isolates from one or more (if
morphologically distinct) colonies were serotyped by
standard methods [24, 25] using sera from Statens
Serum Institut (SSI), Denmark. After ﬁnal identiﬁ-
cation, all Pnc isolates were stored in glycerol blood
broth atx80 xC.
Analysis
Descriptive data analyses were performed in
Microsoft Excel. Conﬁdence intervals on risk ratios
were calculated using Taylor series in Epi-Info
Version 6 (CDC, Atlanta, GA, USA). The number of
times a new serotype was introduced in the family was
derived for diﬀerent age groups. A new introduction
was deﬁned as the situation in which one family
member was found to be carrying a serotype that was
not present in that family at the previous test point.
Ongoing was deﬁned as the type carried at the pre-
vious test point by either the same individual in the
family or other family members and concurrent as
someone else in the family carrying the same type at
the same time. Serotype-speciﬁc odds ratios (ORs)
were calculated with use of serotype 14 as the refer-
ence group as described by Bruggemann et al. [26].
RESULTS
Household
A total of 132 families gave informed consent (rep-
resenting 534 persons including 151 index children).
Household relationship to the index cases included
132 mothers (24.7%), 125 fathers (23.4%), 101 sib-
lings (18.9%) and 25 others including three grand-
parents.
Household data was available on 129 families : they
came from across the socio-economic and educational
spectrum, with 23 (17.8%) living in local authority-
owned rental accommodation and 103 (79.8%) in
owner-occupied housing. Household size ranged
from two to seven persons (mean and median four
persons).
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Although 132 families were recruited, 11 withdrew
before the ﬁrst swab. Of the remaining 121 families,
106 remained until the end of the study (overall drop-
out rate of 20%). Of the 26 families that failed to
complete the entire study, three families immediately
withdrew before completing the household question-
naire, four withdrew due to discomfort of NP swabs,
three had social reasons (i.e. separation) that made it
unreasonable to expect them to continue in the study
and the remaining 16 withdrew either due to in-
convenience related to time involved or because they
left the country.
Individual
Demographic and health
In total, 121 families (with 138 index cases) were
visited at least once by the study nurse (representing a
total of 489 individuals).
Prevalence of Pnc carriage
NP swabbing was performed at least once in these 489
individuals. This represents 121 families out of the 129
that started the study, with eight families leaving the
study during the ﬁrst month and thus, never being
swabbed. In total 3753 swabs were taken from these
489 individuals (77%) and 932/3752 (25%) were
positive for Pnc carriage. Among those 121 families
that started the study the acceptance rates gradually
fell over the study period, although they remained at
y70% or above, throughout.
Mean prevalence of carriage by age group over the
entire study period ranged from 52% for age groups
0–2 years, 45% for 3–4 years, 21% for 5–17 years to
8% for those aged o18 years. There were no signiﬁ-
cant seasonal diﬀerences in the prevalence of carriage
by age group over the 10-month period from October
to July (Fig. 1) (t test trend>0.05 for all age groups).
Among all study participants, 282/489 (58%) in-
dividuals were found to be Pnc carriers at least once
throughout the study period. At least one episode of
pneumococcal carriage was noted amongst 112 of the
121 families swabbed (93%) over the study period.
When stratiﬁed by age the proportion carrying Pnc at
least once ranged from 86% in the 0–2 years age
group to 36% in those aged o18 years (Fig. 2).
Indeed, among the 0–2 years group, 39% were found
to carry Pnc more than ﬁve times during the study
follow-up time compared to 1% of those o18 years
(Fig. 2).
Simultaneous carriage of more than one serotype in
an individual at a particular time-point was only de-
tected on six (0.16%) occasions. Five of the in-
dividuals weref5 years of age.
Distribution of serogroups/types and vaccine coverage
In total, 901/932 (97%) pneumococcal isolates were
serotyped (the remainder being non-capsulate) : 575
(98%) in age group 0–2 years, 93 (95%) in the 3–4
years group, 88 (92%) in the 5–17 years group and
144 (97%) in those aged o18 years. In one circum-
stance the age was not recorded. Thirty-four distinct
serotypes were found in the isolates (Fig. 3). The most
prevalent ﬁve serotypes in children aged 0–2 years
were 6B followed by 19F, 23F, 6A and 14. Among
those personso3 years old, serotypes 6A followed by
23F, 14, 19F and 6B were again the most frequent,
although isolates of 6B were much less frequently
found compared to those aged 0–2 years.
Overall the 7-valent conjugate vaccine protected
against 64% of the circulating serotypes when no
cross protection between serotypes within serogroups
was assumed (Table, Fig. 3). The potential coverage
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was 82% when cross protection was assumed.
Coverage for the 9-valent vaccine was identical to the
7-valent vaccine as serotypes 1 and 5, the additional
types contained in the 9-valent were not observed in
this study. An 11-valent vaccine would provide a
small amount of additional coverage compared to the
7- or 9-valent groups.
By age group, potential vaccine coverage was
highest in those<3 years of age aty70% if no cross
protection within serogroups was assumed, rising to
88% assuming cross protection (Table). Coverage
declined to 50–60% for the older age groups. Gaps in
coverage were particularly due to the non-vaccine
serogroups 11, 16 and 22.
Antibiotic resistance
For the 932 isolates, the proportion with any erythro-
mycin resistance (alone or in combination) was 10%
and the proportion with any degree of penicillin re-
sistance (alone or in combination) was 3.7%.
Cefotaxime resistance was noted in only 0.3% of
isolates. The most common serotypes showing resist-
ance to at least one of the three antibiotics were sero-
types 14 (45%, n=92), 19F (11%, n=128), 6B (14%,
n=214), 6A (4%, n=117), 23F (4%, n=117) and 9V
(17%, n=23). These serotypes represent 90% of all
serotypes that are resistant to one or more of these
three antibiotics. All of these serotypes (including
cross-protection) are included in the 7-valent PCV.
Comparison with invasive isolates
Comparison of the distribution of carriage serotypes
with the distribution of invasive Pnc isolates in
England and Wales reported during 2000 demon-
strated large diﬀerences in odds ratios between sero-
types (Fig. 4). Serotypes 1 (OR 15.1), 4 (OR 6.3), 7F
(OR 15.7) and 8 (OR 10.4) in particular were more
likely to be invasive than carried compared to the
reference serotype 14. The 7-valent Pnc conjugate
vaccine does not cover three of these serotypes (1, 8
and 7F).
Role of the household
The relative importance of intra- and extra-household
exposure to Pnc infection by age group was evaluated
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Table. Coverage of the 7-, 9- and 11-valent vaccines in
diﬀerent age groups
Coverage
Age group (years)
Total0–2 3–4 5–17 o18
No cross protection
7- and 9-valent 70% 52% 53% 55% 64%
11-valent 71% 53% 53% 60% 65%
With cross protection
7- and 9-valent 88% 76% 64% 76% 82%
11-valent 88% 77% 64% 81% 84%
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by examining introductions of new serotypes into the
household (Fig. 5). A marked age-speciﬁc role for ﬁrst
introductions was demonstrated: 25% of ﬁrst in-
troductions were due to individuals in their ﬁrst year
of life, 20% in the second and 19% during the third
year. This then declined to an average of 5.5% per
year for those aged 3–4 years and to 1% per year for
ages 5–17 years.
The eﬀect of within family exposure on pneumo-
coccal carriage was also assessed by examining the
number of changes in individual status over the ob-
servation intervals stratiﬁed by age group and back-
ground carriage in other family members. Individual
pneumococcal carriage was found to be associated
with carriage in the other family members by age
group with risk ratios of 1.42 (95% CI 1.26–1.61),
1.25 (95% CI 0.95–1.64) and 2.25 (95% CI 1.65–3.08)
for age groups 0–2, 3–4 ando5 years respectively.
DISCUSSION
There are few longitudinal studies of Pnc carriage in
the literature, and even fewer studies that have
swabbed both children and adults in a closed setting
such as a household [18, 27]. This study clearly shows
that despite the invasive nature of swabbing studies, it
is possible to achieve and maintain high levels of
compliance over a sustained period of time, although
as with other studies [27] obtaining samples from
some groups such as adult males can be more diﬃcult.
The study conﬁrms that NP carriage of Pnc is
common in the United Kingdom, with y60% of in-
dividuals and 93% of families carrying the organism
at least once over a 10-month period. As has been
reported previously [5, 18, 27], higher carriage rates
are observed in children<5 years of age compared to
older family members. Indeed, in this study approxi-
mately half of the children<3 years of age carried the
organism for over half of the total study period, which
is in agreement with a previous study conducted in
Oxford [8]. This presumably reﬂects both longer dur-
ation of carriage in children, as has been previously
reported [4, 10] together with more frequent acqui-
sition compared to adults. Our results also suggest
children are frequently the route of entry of the
bacterium into the household, with a preponderance
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of those identiﬁed to be carrying for the ﬁrst time
being young children. Although this ﬁnding could
be confounded by children tending to carry Pnc
for longer periods than adults, recent modelling work
has conﬁrmed the important role of children in
introducing Pnc into households, despite longer
duration of carriage [19].
The prevalence of carriers appeared constant
throughout the study period, with no evidence of
seasonal ﬂuctuations. Results from previous studies
have been mixed with some demonstrating an increase
in carriage during the winter months [6, 28], whereas
others have not [7]. The reasons for these diﬀer-
ences are uncertain. However, since pneumococcal-
associated disease (invasive disease, pneumonia and
otitis media) all peak in the winter, it is important to
understand whether such increases in disease are due
to increased carriage (which this study suggests not)
or other mechanisms, such as exposure to other res-
piratory pathogens [such as inﬂuenza or respiratory
syncytial virus (RSV)], which may contribute to the
pathogenic process.
The serotype distribution was broadly similar to
that observed in two previous studies conducted in
diﬀerent geographical settings in England [8, 18]. No
additional protection against carriage was provided
by the 9-valent formulation of the vaccine, as the two
additional serotypes that are present in the latter (1
and 5) were again not found in this carriage study.
However, a comparison with the distribution of in-
vasive isolates reported to the national surveillance
system to those in the carriage study, found some
serotypes were more likely to be invasive than carried.
Several of these serotypes, e.g. serotype 1 are not
covered by the 7-valent vaccine. These serotype-
speciﬁc variations in ‘ invasiveness ’ have been noted
by other groups both in the United Kingdom [26] and
elsewhere [10]. However, this comparison should be
undertaken with caution as it is well documented that
serotype-speciﬁc duration of carriage varies – thus,
serotype 1 for example, may be carried more widely,
but for a very short period of time.
The rates of antimicrobial resistance observed in
this carriage study compare to the rates observed for
invasive isolates in 2000 for the United Kingdom.
Observed rates were lower for both penicillin (3.7%
for the carriage study vs. 7% for invasive disease) and
erythromycin resistance (10% in the current study vs.
15% for invasive disease). The vast majority of sero-
types demonstrating antibiotic resistance would be
covered by a 7-valent PCV.
One of the concerns expressed about the introduc-
tion of Pnc conjugate vaccines into national im-
munization programmes has been replacement with
non-vaccine serotypes. In the United States, a large
reduction in invasive Pnc disease rates has
been observed since the introduction of the infant
immunization programme particularly in young
children [29]. More recently, a signiﬁcant increase in
serotype replacement with non-vaccine serotypes has
been published [17] In this study simultaneous car-
riage with more than one serotype was not detected
commonly, suggesting that unmasking is not likely to
be an important component of any potential serotype
replacement. However, this still leaves the issue of
replacement. This study together with long-term
studies and ongoing surveillance will provide valuable
data to better understand the transmission dynamics
of Pnc and thus, the potential importance of replace-
ment.
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